ICU patients may need custom doses for fungal infections
NCT ID NCT02164890
First seen Nov 21, 2025 · Last updated May 16, 2026 · Updated 21 times
Summary
This study looked at how the antifungal drug micafungin behaves in 60 critically ill ICU patients with invasive candidiasis, a serious fungal infection. The goal was to see if standard doses reach effective levels in these patients, since their bodies often process drugs differently. Researchers measured drug concentrations over time to understand variability and improve future dosing strategies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INVASIVE CANDIDIASIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHU de Montpellier
Montpellier, 34295, France
Conditions
Explore the condition pages connected to this study.